Next Article in Journal
Urinary Metabolites Variation After High-Intensity Rowing Training and Potential Biomarker Screening for Exercise-Induced Muscle Damage
Previous Article in Journal
SALL2-Mediated Suppression of WNT Signaling Through Transcriptional Control of AXIN2 in Colorectal Cancer Cells
Previous Article in Special Issue
Human Glucose Transporters in Health and Selected Neurodegenerative Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 16
10.3390/ijms26167899
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives

by
Lorenz A. Scherpinski
1,
Jörg König
1,2 and
Renke Maas
1,2,*
1
Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
2
FAU NeW Research Center New Bioactive Compounds, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(16), 7899; https://doi.org/10.3390/ijms26167899
Submission received: 19 July 2025 / Revised: 9 August 2025 / Accepted: 11 August 2025 / Published: 15 August 2025
(This article belongs to the Special Issue Transporters in Health and Disease)
Browse Figures
Versions Notes

Abstract

L-arginine and its derivatives L-homoarginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) show distinct (patho-) physiological properties as well as a differential renal handling. L-arginine and L-homoarginine have a lower renal clearance and are largely retained (i.e., reabsorbed) as compared to ADMA and SDMA, which are relatively enriched in the urine and excreted. To obtain a more complete picture of what is known regarding transport proteins involved in renal reabsorption and secretion of these substances, a comprehensive literature review and search of cell-specific gene expression databases were performed. Five transport proteins known to transport L-arginine and its derivatives were included, and the data available regarding their tubular expression pattern and their transport characteristics, as well as experimental and clinical data regarding their possible impact on the renal handling of L-arginine and its derivatives, are presented and discussed in a structured narrative review. Based on their transport properties and links to clinical phenotypes, b0,+AT-rBAT and y+LAT1-4F2hc were identified as the most promising candidates to explain a significant part of the observed differential renal handling. This also makes them promising candidates for further investigations as mediators of possible adverse and beneficial drug effects involving L-arginine, L-homoarginine, ADMA, and SDMA.

1. Introduction

L-arginine and its derivatives L-homoarginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA) play an important role in cardiovascular health [1,2,3,4,5,6,7], with the L-arginine-nitric oxide (NO) pathway as a major connecting mechanism regulating endothelial function and vascular tone [8]. Elevated ADMA or SDMA plasma concentrations predict adverse cardiovascular outcomes and death [5,9,10]. A proposed contributing mechanism is their inhibitory effect on NO synthesis, either by competitively inhibiting nitric oxide synthase (NOS) [5,10] or by interference with protein-mediated arginine transport into cells [11,12]. These mechanisms could be the reason why increased plasma concentrations of ADMA and SDMA correlate with cardiovascular disease and mortality [3]. In contrast, L-homoarginine has been associated with protective cardiovascular effects, and reduced plasma concentrations have been linked to adverse outcomes in both kidney and cardiovascular diseases [7,13,14,15].
The risk of cardiovascular disease is increased by two to four times in patients with chronic kidney disease (CKD) [16], and accumulation of uremic toxins, including ADMA and SDMA, or loss of protective factors like L-homoarginine, have been implicated as contributing factors [2,3,5]. The kidney is a main organ of homeostasis for L-arginine, L-homoarginine, ADMA, and SDMA. However, despite their similar chemical structures, these four molecules are processed differently by the kidneys, which is reflected by their renal plasma clearance values: while L-arginine and L-homoarginine exhibit low clearance rates (0.12–0.27 mL/min [17,18,19] and 1.06–1.50 mL/min [17,18], respectively), indicating substantial reabsorption or retention, ADMA and SDMA show a higher clearance (77.50–85.74 mL/min [17,20] and 80.10–81.73 mL/min [17,20], respectively), pointing to predominant urinary excretion. These differences in clearance suggest distinct renal handling mechanisms that extend beyond glomerular filtration alone.
Renal plasma processing involves not only filtration, but also tubular transport, local synthesis, and metabolic transformation. L-arginine and L-homoarginine are not only reabsorbed after glomerular filtration into proximal tubule cells but are also synthesized intracellularly and released into blood [21,22]. In contrast, the methylarginines ADMA and SDMA, which primarily remain in the urine after glomerular filtration, are also metabolized by enzymes in proximal tubule cells, requiring uptake from either the tubular lumen or the peritubular capillaries [6,23,24,25,26]. The uptake and release of L-arginine and its derivatives into and out of renal tubular cells are mediated by transport proteins [12,27,28,29,30,31].
So far, a total of 19 different transport proteins have been shown or proposed to mediate the transport of L-arginine and its derivatives (see review by Banjarnahor et. al. [30]). No transport protein has yet been identified that facilitates the transport of L-homoarginine, ADMA, or SDMA without also transporting L-arginine. However, only some of these 19 transporters are expressed in the kidney and are, therefore, likely to be involved in renal handling. Previous suggested models describing the transporter environment in the proximal tubule focused only on L-arginine and did not cover the mechanisms behind the distinct renal handling of the arginine derivatives such as ADMA, SDMA, and L-homoarginine [32,33].
Given their distinct role as nutrients, signaling precursors, and protective factors in the case of L-arginine and L-homoarginine, as opposed to possible detrimental effects attributed to ADMA and SDMA as uremic toxins, a differential renal handling of these chemically related substances comes as no surprise. However, to our best knowledge, the underlying transport mechanisms have never been systematically assessed until now.
The scope of this review is the handling of L-arginine and its derivatives by transport proteins, expressed in the human kidney, with a focus on transporters expressed in proximal tubule cells. Recent findings and advances in single-cell transcriptomics allow us to reassess the role of these transporters in the physiology and renal handling of L-arginine and its cardioactive derivatives in new detail.

2. Cardioactive Arginine Derivatives

A general overview of L-arginine and its derivatives is compiled in Table 1.

2.1. L-Arginine

As a semi-essential amino acid, L-arginine is part of protein synthesis and multiple metabolic and signaling pathways [21,34]. For its daily supply, the body relies on diet (4–5 g per day [21]), endogenous synthesis (2 g per day [21]), and release from protein turnover. Endogenous L-arginine synthesis primarily occurs in the kidneys from citrulline via argininosuccinate synthase and lyase [21,35,36]. The progression of CKD leads to only minor changes in plasma L-arginine concentrations [4,37,38,39], likely due to compensatory mechanisms such as increased synthesis from citrulline [37,40].
L-arginine is the precursor of the vasodilator NO [8], which is produced by NOS enzymes [41]. NOS metabolize L-arginine or L-homoarginine to NO and L-citrulline or L-homocitrulline, respectively [8,42]. Consequently, L-arginine supplementation and a high-protein diet were investigated as possible therapies for high blood pressure and showed significant results in short-term interventions [43,44,45,46]. Long-term supplementation of 9 g L-arginine daily was associated with increased mortality in a single study [47]. However, long-term supplementation of L-arginine may have only a limited impact on plasma L-arginine, possibly due to counterregulatory mechanisms. Supplementation of its metabolic precursor citrulline may be much more efficient with respect to elevating plasma L-arginine [48].

2.2. L-Homoarginine

L-homoarginine is a non-proteinogenic cationic amino acid. It is a dietary component but also synthesized from lysine by the enzyme arginine:glycine amidinotransferase (AGAT) [49], which is expressed in multiple organs but to the greatest extent in the kidney [49]. It has been characterized as an independent protective marker for mortality in coronary heart disease and hemodialysis patients [7,15]. The cardioprotective properties have, in part, been attributed to its role as a secondary substrate of NOS for NO synthesis [42]. Similar to L-arginine, it is part of the glomerular filtrate and largely reabsorbed in the renal tubules [17].
With advancing renal impairment, homoarginine plasma concentrations decrease [2,13]. However, whether the inverse correlation of its plasma concentration and the estimated glomerular filtration rate (eGFR) of the kidney depends on a decline in renal reabsorption or synthesis is not fully understood.

2.3. ADMA

ADMA serves as a direct inhibitor of NOS [5,10]. Elevated plasma concentrations of ADMA are independently associated with elevated total and cardiovascular mortality [3], of which inhibition of NOS has been proposed as a possible mechanism [3,5]. ADMA originates from protein degradation of previously methylated arginine [50,51]. Around 80% of ADMA is metabolized by the enzymes dimethylaminohydrolase 1 (DDAH1) [9,52] and, to a minor degree, by alanine-glyoxylate aminotransferase 2 (AGXT2) [53]. DDAH1 is expressed widely in different tissues, including the kidney, pancreas, and liver [52]. AGXT2 is mainly expressed in the kidney and the liver [54]. The remaining ADMA is renally eliminated [25,55]. ADMA was originally characterized as a uremic toxin in hemodialysis patients and patients with kidney failure [5]. To investigate the impact of the eGFR on the renal plasma clearance of ADMA in humans, Ronden et al. took renal artery and vein samples of hypertension patients with mild to moderate renal insufficiency [25]. They could show that the eGFR is not independently associated with the renal plasma clearance of ADMA, with only a minor decrease in the renal plasma clearance between the different eGFR groups [25]. The persistence in renal plasma clearance independent of the eGFR indicates that ADMA is taken up from the blood into proximal tubule cells and metabolized there instead of being filtered. Additionally, Carello et al. reported that ADMA plasma clearance persisted after total nephrectomy in rats while SDMA levels were rising, indicating that renal ADMA elimination can be compensated by hepatic DDAH1 [56]. It was also shown that cirrhosis patients have elevated ADMA concentrations that are lowered again after compensated cirrhosis was accomplished [57].
Table 1. Key characteristics of L-arginine and its derivatives in healthy and CKD patients (adapted and extended from Banjarnahor et al. [30]).
Table 1. Key characteristics of L-arginine and its derivatives in healthy and CKD patients (adapted and extended from Banjarnahor et al. [30]).
L-ArginineL-HomoarginineADMASDMA
StructureIjms 26 07899 i001Ijms 26 07899 i002Ijms 26 07899 i003Ijms 26 07899 i004
Source or synthesisEndogenous: via biosynthesis between 9.2 and 16 µmol*kg−1*h−1 equals ~2.8–5 g/day in male adults [58,59]Endogenous: synthesis by the enzyme AGAT [49]Endogenous: hydrolysis of proteins after asymmetric methylation (~60 mg/day) [23,50,51]Endogenous: hydrolysis of proteins after asymmetric methylation [23,50,51]
Diet: approx. 5 g/day [60]Diet: unknown proportionDiet: unknown proportionDiet: unknown proportion
Metabolism and eliminationMajor enzymes: AGAT, NOS (3 isozymes), arginases (2 isozymes), and L-arginine decarboxylase [21,34]Major enzymes: AGXT2 [61]; arginases and NO-Synthases [42,62]Major enzymes: DDAH1
accounts for >80% of the metabolic elimination [9,52]; AGXT2 [53]
Elimination: renal excretion ~20% [25,55]		Major enzyme: AGXT2 (mildly elevated plasma concentration in genetic AGXT2 deficiency) [53]
Elimination: primarily by renal excretion [25,56]
Protein
binding		<4% [63]No data found8% [23]9% [23]
Plasma concentration
mean values
[µmol/L] 		83–153 [4,20,64,65,66,67,68] 1.19–2.5 [65,69,70]0.23–0.67
[4,26,65,66,67,71,72]		0.15–0.53 [4,26,65,66,72,73]
Renal clearance [mL/min]0.12–0.27 [17,18,19]1.06–1.50 [17,18]77.50–85.74 [17,20]80.10–81.73 [17,20]
Effect of impaired renal clearance on plasma concentrationUnchanged [4,37,38,39]Lowered ~30% [13]Elevated ~10–100% [4,5,26,66,74]Highly elevated ~50–1000% [4,26,66,74]
* ADMA: asymmetric dimethylarginine; SDMA: symmetric dimethylarginine; AGAT: L-arginine:glycine amidino transferase; NOS: NO synthases; AGXT2: alanine —glyoxylate aminotransferase 2; DDAH1: Dimethylarginine dimethylaminohydrolase 1.

2.4. SDMA

For a long time, SDMA was considered biologically inert [5]. However, recent studies could show that SDMA can increase monocytic reactive oxygen species production [75], activate NF-κB [76], influence several immunologically relevant transcription factors [77], and is a weak inhibitor of L-arginine transport [12,29,78]. Like ADMA, SDMA is produced during protein degradation [23,50,51]. SDMA is poorly metabolized except in small amounts by AGXT2 [53], and single-nucleotide polymorphisms in the AGXT2 gene in mouse and humans are associated with a mild increase in plasma concentration [53,79]. However, the main route of elimination is via the kidneys [25,56], where it correlates stronger with eGFR than ADMA [4]. Therefore, multiple studies investigated SDMA as a biomarker for CKD, where it showed promising results in predicting CKD progression [4,5,36,74,80]. In a chronic SDMA infusion mouse model, Veldink et al. demonstrated that a significant increase in SDMA plasma concentration from 0.26 ± 0.1 to 3.49 ± 1.66 µM did not result in changes in renal or cardiac function [81]. These findings suggest that the close inverse correlation between the plasma concentrations of SDMA and the eGFR may primarily drive its association with all-cause mortality, aside from its weak NOS-inhibiting effects [42].

3. Renally-Expressed Transport Proteins Related to L-Arginine Transport

A total of 19 transport proteins have been identified mediating the transport of L-arginine [30,78]. However, only eight transport proteins are expressed in kidney cells: CAT1 (gene: SLC7A1), CAT2 (gene: SLC7A2), y+LAT1-4F2hc (gene: SLC7A7/SLC3A2), y+LAT2-4F2hc (gene: SLC7A6/SLC3A2), b0,+AT-rBAT (gene: SLC7A9/SLC3A1), OCT2 (gene: SLC22A2), OATP4C1 (gene: SLCO4C1), and MATE1 (gene: SLC47A1), making them the only ones likely to be relevant to renal handling [82,83,84,85,86,87,88,89,90,91]. Most of the expression data available, so far, were based on whole organ analysis instead of single-cell assays, causing uncertainty about whether these proteins are also expressed in the renal tubular system. However, in recent years, several comprehensive database projects aimed to close this gap by providing publicly available single-cell RNA (scRNA) data sets. For the present analysis the scRNA expression data provided by the Human Protein Atlas (HPA) [92,93,94,95,96,97,98,99,100,101,102] and the Kidney Tissue Atlas (KTA) (The KTA data were generated by the Kidney Precision Medicine Project. https://www.kpmp.org (accessed on 4 March 2025) [93,103]) were used to assess and visualize which transport protein is expressed in which part of the tubular system (Figure 1).
The expression patterns were comparable in both databases. Transport proteins located in the apical membrane were predominantly expressed in proximal tubule cells, enabling only these cells to reabsorb L-arginine or its derivatives. Other segments of the tubular system showed only basolateraly expressed transporters, which can take up L-arginine from the blood, e.g., for protein synthesis. In proximal tubule cells, scRNAs of the following apically localized transport proteins were detected: b0,+AT-rBAT, and MATE1, and at the basolateral side y+LAT1-4F2hc, OCT2, and OATP4C1. The KTA has a higher resolution analysis of the tubular system compared to HPA and separates the proximal tubule further into multiple segments. These data indicate that SLC7A9/SLC3A1 and SLC7A7/SLC3A2 are mainly expressed in the first two proximal tubule segments.
For CAT1, CAT2, and y+LAT2, we found no evidence of expression in the proximal tubule. In previous works, CAT1 had been proposed to be part of the renal arginine homeostasis [33,104]. However, both single cell expression databases we utilized show that the SLC7A1 gene, encoding CAT1, is not expressed in the proximal tubule but rather in the collecting duct. These findings are in line with reports of CAT1-associated NO production in the collecting duct of rats [105,106].
The expression pattern narrows the number of potential transport proteins responsible for arginine derivative homeostasis down to five candidates, which are further described in more detail (Figure 2).

3.1. y+LAT1 (SLC7A7) and 4F2hc (SLC3A2)

The y+L amino acid transporter 1 (y+LAT1) is encoded by the SLC7A7 gene. It is one of the two members of the y+L transport system. Together with the anchor protein 4F2hc (gene SLC3A2), it forms a heterodimeric protein, in which the 4F2hc is necessary for plasma membrane localization [88,107]. Both proteins are regulated by mTOR, which is activated, among other things, by intracellular amino acid deficiency [108]. The transporter is located in the basolateral membrane of proximal tubule cells, especially in segment 1/2 (Figure 1) and in intestinal cells [82,88], with protein expression confirmed by immunohistochemistry in rodent kidney tissue [104]. In these cells, y+LAT1-4F2hc acts as an exchange protein that mediates a cationic amino acid efflux coupled to a Na+ and neutral amino acid influx [32,109,110]. This results in an approximately five-fold gradient between cationic (lower in the cytosol) and neutral (higher in the cytosol) amino acids [32,110]. In the absence of Na+, y+LAT1-4F2hc loses its affinity to neutral amino acids and transports only cationic amino acids, which are transported independently of Na+ [82]. Transport kinetic studies in monocyte-derived macrophages showed an apparent Km value of 182 µM for L-arginine (Table 2) [111]. For the arginine derivatives, no kinetic parameters have been identified so far.
Nevertheless, two case reports give insights into possible interactions between L-homoarginine, ADMA, and y+LAT1-4F2hc. In a patient with lysinuric protein intolerance (LPI), a disease caused by mutations in the SLC7A7 gene, Kato et al. observed elevated L-homoarginine urine concentrations by a factor of 63 to 563 as compared to controls [69]. This indicates that the release of L-homoarginine into blood after renal reabsorption is largely mediated by y+LAT1-4F2hc [69]. LPI patients also have lower L-arginine plasma concentrations and elevated urinary L-arginine concentrations [69]. This may explain why LPI is also associated with reduced NO production and endothelial dysfunction [116,117]. A connection between y+LAT1-4F2hc and ADMA was reported by Closs et al. [112]. They observed an increased intracellular ADMA concentration in a patient with reduced y+LAT1 expression [112]. They hypothesized that y+LAT1 expression mediates ADMA efflux out of the cells and that this mechanism is an additional factor contributing to reduced endothelial function in LPI, since ADMA is a known inhibitor of eNOS [5,112]. For further reading on the role of y+LAT1 in other tissues, we recommend the following reviews [82,110].

3.2. b0,+AT (SLC7A9) and rBAT (SLC3A1)

b(0,+)-type amino acid transporter 1 (b0,+AT) is the active part of the heterodimeric protein b0,+AT-rBAT, which is encoded by the genes SLC7A9 and SLC3A1. rBAT alone has no transport activity; it functions as an anchor protein for directing b0,+AT to the apical membrane and is joined to b0,+AT by a disulfide bridge [82,118]. Similar to y+LAT1-4F2hc, the gene expression of b0,+AT-rBAT is regulated by mTORC1 [108]. Both genes are expressed in the proximal tubule, although SLC3A1 expression is not limited to this segment (Figure 1). This expression pattern is caused by a second light chain AGT-1 encoded by the SLC7A13 gene, which also forms a heterodimer with rBAT mainly in the S3 segment and distal convoluted tubule [119,120]. However, western blot data from rodent studies confirmed b0,+AT-rBATs limitation to the proximal tubule [121]. b0,+AT-rBAT acts as an obligatory heterodimeric amino acid exchanger [82]. Under physiological conditions, b0,+AT-rBAT mediates the uptake of cationic amino acids or cysteine in exchange for neutral amino acids, independent of sodium [122]. The physiological transport direction is probably based on an intracellular negative membrane potential [82], but, hypothetically, it can also mediate the transport in the opposite direction if the conditions are altered. Why the transporter mediates cationic amino acid and cysteine uptake is not fully understood since cysteine tends to have an anionic character at neutral pH. However, the cryo-EM structure of b0,+AT revealed that the transporter has, next to the classical binding pocket 1, an additional binding pocket 2 [123], while other heterodimeric transporters, such as LAT1 (SLC7A5), have only one binding pocket [124,125]. It is assumed that the second pocket enables this broader substrate spectrum. Different kinetic parameters (Km values) for L-arginine have been reported, depending on the cell model used for analysis, ranging between 108 µM and 512 µM (Table 2) [27,113,126]. Banjarnahor et al. determined a Km value of 197 µM for L-homoarginine in Madin–Darby canine kidney cells (MDCK) overexpressing human b0,+AT-rBAT [27]. The same study also investigated ADMA as a substrate of b0,+AT-rBAT [27]. It was shown that ADMA is also transported; however, due to a lack of saturation, a Km value could not be determined [27]. As mentioned before, b0,+AT-rBAT is theoretically capable of mediating L-arginine transport in both directions. Using chicken jejunal cells, Km values of ~8 µM for uptake and ~180 µM for efflux were reported for the avian b0,+AT-rBAT protein, which highlights the physiologically preferred direction of mediating L-arginine uptake [127,128].
Mutations in b0,+AT-rBAT are associated with cystinuria, a disease in which excessive amounts of cysteine, lysine, arginine, and ornithine remain in the urine [129]. Cystinuria is classified as type A (mutations in rBAT), type B (mutations in b0,+AT), or type AB (mutations in both) [82,130]. Although several key mutations have been identified, data on genotype–phenotype correlations remain limited [129]. There is a case report describing a specific mutation in the b0,+AT binding pocket, which converts the transporter into a specific cationic amino acid transporter [82,131]. Based on the mutation, the degree of cystinuria can differ between patients. Cox et al. reported that urinary excretion of L-arginine changed from 7–35 µmol/24 h in healthy individuals to 1455–8670 µmol/24 h in cystinuria patients [18]. The same study reported a urinary excretion of 15–51 µmol/24 h for L-homoarginine in cystinuria patients, as compared to 1–6 µmol/24 h in controls [18], indicating that L-homoarginine reabsorption from the urine is mainly mediated by b0,+AT-rBAT. The elevated amounts of L-arginine and L-homoarginine in the urine of cystinuria patients suggest that b0,+AT-rBAT is a major, if not the main, renal mediator for the reabsorption from the urine and is, thus, likely to be one key player in the homeostasis of L-arginine and its derivatives [30]. Whether SDMA is a substrate of the b0,+AT-rBAT is still unknown and remains to be investigated. For further reading on the role of b0,+AT-rBAT in other tissues, we recommend the following reviews [82,110].

3.3. OATP4C1 (SLCO4C1)

The organic anion transporting polypeptide 4C1 (OATP4C1) is encoded by the SLCO4C1 gene which is mainly expressed in proximal tubule cells (Figure 1) [132], where the protein locates at the basolateral membrane [89]. OATP4C1 is a bidirectional Na+-independent transporter and has a broad substrate spectrum, ranging from endogenous compounds such as thyroid hormones, cyclic AMP, to uremic toxins (including ADMA) and xenobiotics like digoxin [29,30,89,133]. ADMA is taken up by OATP4C1 from blood into proximal tubule cells (uptake Km value 232.1 µM) [29,114]. For L-arginine, L-homoarginine, and SDMA, the physiological transport direction is not fully investigated. OATP4C1 can mediate the uptake (Km values: 48.1 µM L-arginine, 49.9 µM L-homoarginine, and 70 µM SDMA) and the efflux of all three substances (Table 2) [29,115]. The Km values of ADMA, SDMA, and L-homoarginine, but not of L-arginine, are above the physiological plasma concentrations, which raises questions about the contribution of OATP4C1 to the homeostasis of these substances [29,115]. However, two animal studies in cats and rats demonstrated a significant decline in SLCO4C1 mRNA expression in CKD cohorts compared to healthy controls, suggesting that transporter downregulation may be involved in the disease-associated changes in solute handling [134,135]. A possible cause for the downregulation could be indoxyl sulfate, another uremic toxin which accumulates during CKD. It was shown that indoxyl sulfate downregulates OATP4C1 gene expression in a concentration-dependent manner [136]. In addition, Toyohara et al. showed in a rat model that statin administration increased renal SLCO4C1 mRNA expression, accompanied by a significant rise in ADMA elimination [114]. These findings imply that, despite its relatively high Km value, OATP4C1-mediated ADMA transport may play a relevant physiological role.

3.4. OCT2 (SLC22A2)

The organic cation transporter 2 (OCT2) is encoded by the SLC22A2 gene, which is primarily expressed in the kidney [90,91]. Studies in rodents suggest that the gene expression is regulated by sex hormones like testosterone [137]. In the proximal tubule, OCT2 is located at the basolateral membrane [138], where it mediates the uptake of several cationic molecules [90]. Interestingly, rodent proximal tubule cells also express the closely related transport protein Oct1. Due to the overlapping substrate spectrum of Oct1 and Oct2, Oct2-deficient mice−/− show no changes in renal function compared to wild type animals [139]. However, this compensatory mechanism does not exist in humans and should be considered when comparing human and animal data. The broad substrate spectrum of OCT2 includes endogenous molecules, for example, creatinine, N1-methylnicotinamide, and uremic toxins, as well as several drugs such as metformin, varenicline, or antiretrovirals, which make OCT2 an important site of drug interactions and off-target drug effects [140,141]. OCT2 facilitates the first step in renal secretion of cationic drugs by mediating the drug uptake into proximal tubule cells out of the blood, followed by an efflux into tubular filtrate mediated by MATE1 [142]. As a result, various pharmacologically important drug–drug interactions are associated with OCT2 [143], which is the reason Galetin et al. categorized OCT2 as a clinically important transporter of category A [144]. They further recommended that during drug development, OCT2 interactions should be monitored by changes in the N1-methylnicotinamide levels as an endogenous biomarker of OCT2 [144]. Additionally, several pharmacologically relevant polymorphisms in the SLC22A2 gene have been identified, most of which are associated with altered drug disposition rather than disease phenotypes [30].
Further characteristics of OCT2-mediated transport include its sodium independency, bidirectionality, and dependence on the membrane potential [142,145]. The cationic substrate preference of OCT2 led to investigations about whether L-arginine, ADMA, or SDMA are also substrates [28,115]. OCT2 is capable of mediating the transport of all three substances; however, the high Km values of >10,000 µM for L-arginine, 900 µM for ADMA, and no saturation reached for SDMA indicate a low affinity and suggests that OCT2 may play a minor role at physiological concentrations (Table 2) [28,115]. Nonetheless, the impact of OCT2-mediated SDMA transport should not be dismissed too readily: although 1 µM SDMA was used in this study, even a 100-fold higher concentration of the OCT2 inhibitor cimetidine (100 µM) inhibited uptake by only 75%, indicating that SDMA is not easily displaced. This may point to a more complex interaction with OCT2 than suggested by the lack of saturation [115]. Currently, there are no available data on OCT2-mediated transport of L-homoarginine. Despite these findings, the physiological relevance of OCT2 in handling endogenous compounds such as methylated arginines remains uncertain. Historically, research on OCT2 has focused on its role in drug disposition. More recently, however, biomarker research has drawn attention to its relevance for the transport of endogenous compounds [146,147]. In vitro studies showed the inhibitory potential of different uremic toxins that accumulate during the progression of CKD, leading in vivo to further changes in drug secretion [141,148]. ADMA was among the substances tested by Cheung et al. as potential inhibitors of metformin uptake; however, even at concentrations 100 times higher than physiological plasma levels, it showed only minimal inhibition (approximately 4%) [148]. However, dimethylamine, the product of DDAH1-mediated ADMA degradation, was identified as an inhibitor [148]. In summary, the role of OCT2 in the homeostasis of L-arginine and its derivatives remains unclear and needs further investigation, particularly concerning the transport of the uremic toxins ADMA and SDMA.

3.5. MATE1 (SLC47A1)

The multidrug and toxin extrusion protein 1 (MATE1) is encoded by the SLC47A1 gene and expressed in several tissues, with the highest expression in the liver and kidney [83]. In the tubular system of the kidney, the expression is restricted to the proximal tubule (Figure 1), where MATE1 is located in the luminal membrane (Figure 2) [83,138]. The transport is sodium-independent but coupled to a H+ exchange, making the transport direction dependent on the pH gradient [83]. Under physiological pH conditions, MATE1 predominantly mediates the efflux out of cells, but for experimental studies MATE1 can be analyzed as an uptake transporter by changing the pH of the uptake buffer. Such an experimental setup should only be applied to substances whose formal charge remains unchanged under these modified conditions. MATE1 mediates the renal elimination of multiple endogenous and exogenous substrates like creatinine, trimethylamin-N-oxide (TMAO), or metformin after OCT2-mediated uptake into proximal tubule cells [83,146,149]. Due to its role in drug elimination and potential for significant drug–drug interactions, comparable to OCT2, MATE1 has also been designated a clinically important transporter in category A [144]. Irrespective of drug interactions, high fluctuations in the renal elimination of metformin were observed between patients [150]. Following up on these findings, Kajiwara et al. screened 89 Japanese subjects for MATE1 single nucleotide polymorphisms (SNP) and identified 8 SNPs [151]. Three of these SNPs (A310V, D328A, and N474S) significantly reduced the transport ratio, and one SNP (G64D) caused a total loss of function [151]. Due to the wide range of substrates, Strobel et al. investigated L-arginine and ADMA as potential substrates of MATE1. With increasing alkalinization, the highest uptake ratio for L-arginine (100 µM) and ADMA (1 µM) was observed at a pH of 8.2 with 1.31 and 1.24, respectively (Table 2) [28]. Recently, it was shown that MATE1 can also transport SDMA with a Km value of 1973 µM [115].
Regarding CVD, the role of MATE1 in drug excretion may be more significant than its involvement in the handling of L-arginine and its derivatives, as most studies focus on MATE1’s function in drug transport and drug-induced nephrotoxicity [152]. The known endogenous substrate spectrum of MATE1 is relatively limited [83,146,149]. However, ongoing research into biomarkers may reveal novel interactions with endogenous compounds, similar to findings for OCT2. Despite this, the low transport ratios for L-arginine and ADMA [28], along with the very high Km value for SDMA [115], suggest that these substances are relatively poor substrates for MATE1.

4. Conclusions

In this combined assessment of the literature and expression databases, five transport proteins most likely involved in the tubular uptake and release of L-arginine and its derivatives were identified (Figure 1 and Table 2). Taken together, the experimental and clinical data detailed above indicate that, of these, the heterodimeric protein b0,+AT-rBAT (encoded by SLC7A9 and SLC3A1) and y+LAT1 (encoded by SLC7A7) with its anchor protein 4F2hc (encoded by SLC3A2) are the most plausible candidates involved in the observed differential renal handling of L-arginine, L-homoarginine, ADMA, and SDMA.

4.1. The Role of Overlapping Substrate Specificities of Tubular Transport Proteins

L-arginine and its derivatives are substrates of several transport proteins with different expression patterns in the body. So far, L-arginine and its derivatives have been identified as substrates for 19 transport proteins [30,78]. Newly available single-cell RNA sequencing data confirm expression of OCT2, y+LAT1-4F2hc, b0,+AT-rBAT, MATE1, and OATP4C1 in the proximal tubule (Figure 1), supporting their role in renal handling of these metabolites [92,93,103]. At first glance, transport of these substances appears to be full of redundancy, as the close chemical properties of L-arginine and its derivatives result in overlapping transport systems (Figure 2). However, these apparent redundancies may serve distinct physiological functions, such as enabling bidirectional transport or ensuring the continuous handling of essential compounds like L-arginine.
The distinct renal handling of the L-arginine derivatives suggests that not all substrates benefit equally from these overlapping systems. A substance that is exclusively filtered by the glomerulus in healthy adults (e.g., inulin) exhibits a renal clearance of around 100–120 mL/min, depending on age [153]. In contrast, the renal plasma clearances of L-arginine (0.12–0.27 mL/min [17,18,19]) and L-homoarginine (1.06–1.50 mL/min [17,18]) indicate efficient reabsorption. By comparison, ADMA (77.50–85.74 mL/min [17,20]) and SDMA (80.10–81.73 mL/min [17,20]) show clearance values closer to that of inulin, suggesting minimal reabsorption and predominant renal elimination. One factor that may contribute to the moderate reduction in clearance of ADMA and SDMA relative to inulin is protein binding. However, the reported binding rates, 8% for ADMA [23] and 9% for SDMA [23], are relatively low and would have only a minor effect on glomerular filtration. Thus, even for these substrates, there appears to be a certain degree of reabsorption from the urine.

4.2. Key Candidates for Differential Transport of L-Arginine Derivatives

In the context of reabsorption, particular attention should be given to the transporter b0,+AT-rBAT, which is the only known luminal transporter capable of mediating the uptake of L-arginine, L-homoarginine, and ADMA, as demonstrated by Banjarnahor et al. [27] (although data for SDMA transport via b0,+AT-rBAT are currently lacking). Notably, for ADMA, no saturation was observed, indicating a substantially lower affinity as compared to L-arginine and L-homoarginine. This difference in affinity may contribute to the observed differences in renal clearance among the three compounds and could help resolve ongoing discussions regarding the mechanism(s) explaining their differential renal handling.
However, reabsorption is not the only factor influencing plasma clearance. A study by Ronden et al. provided further insight, showing that ADMA is not solely dependent on glomerular filtration for its renal elimination but is also absorbed and metabolized from the basolateral (blood-facing) side [25]. In their analysis of CKD cohorts, the renal plasma clearance of SDMA declined by approximately 56% between individuals with eGFR > 90 and those with eGFR 30–59, whereas the decrease for ADMA was only around 26% [25]. This disparity implies either the involvement of basolateral transporters capable of discriminating between ADMA and SDMA or a relatively greater compensatory reserve of metabolic pathways for ADMA as compared to SDMA. Identifying basolateral transporter(s) contributing to a differential uptake remains a challenging objective for future research. The data available, so far, do not present any clear results. Notwithstanding yet unidentified transporters, a contribution of y+LAT1-4F2hc and even OCT2 or OATP4C1 cannot be ruled out.
Moreover, we identified only limited (if any) experimental data regarding the regulation of these transport proteins in the renal tubular system. However, regulation of the transport proteins is a further factor to be considered in future research. A detailed discussion of the regulation of the transport proteins in the tubular system is beyond the scope of this review as regulation/modulation of function is highly complex and data are still limited.
The homeostasis of L-arginine, L-homoarginine, ADMA, and SDMA plasma concentrations is linked, among other factors, to kidney function, albeit to a varying degree, reflecting for each substrate the net effect of the relative contribution of reabsorption and secretion mediated by tubular transport proteins as well as synthesis and/or metabolism in tubular cells. Put into perspective, tubular transport is likely to be an important, but not the sole, factor explaining the observed differential renal handling of L-arginine and its derivatives (see exemplary metabolic pathways in Figure 2). A key limiting factor for advancing mechanistic insight is the lack of adequate proximal tubule cell lines that mirror in vivo gene expression. Khundmiri et al. analyzed fourteen different proximal tubule cell lines from six species and found that the commonly used human cell line HK-2 showed only 26% transcriptomic homology to native proximal tubule cells [154]. This significant discrepancy underscores that functional conclusions drawn from commonly used immortalized proximal tubule models must be interpreted with caution, and highlights the importance of validating transporter function in physiologically relevant systems, ideally using primary cells or in vivo models. To facilitate further research, the authors have made these data publicly available in a searchable database (https://esbl.nhlbi.nih.gov/JBrowse/KCT/ (accessed on 6 June 2025)) [154].
Taken together, transport proteins such as b0,+AT-rBAT and y+LAT1-4F2hc may constitute interesting candidates for pharmacological interventions to modulate the homeostasis and effects of L-arginine-related compounds. Moreover, transporters with clinical evidence for a net impact on the homeostasis of L-arginine derivatives should also be investigated as sites mediating possible adverse drug effects.

Author Contributions

Conceptualization, L.A.S., J.K. and R.M.; writing—original draft preparation, L.A.S.; writing—review and editing, L.A.S., R.M. and J.K.; visualization, L.A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Deutsche Forschungsgemeinschaft (DFG) to JK, grant number (KO 2120/10-1) and RM (MA 3324/7-1).

Acknowledgments

This review is part of the doctoral thesis of L.A.S. This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) to JK (KO 2120/10-1) and RM (MA 3324/7-1).

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
ADMAAsymmetric dimethylarginine
AGATArginine: glycine amidinotransferase
AGXT2Alanine-glyoxylate aminotransferase 2
b0,+ATb(0,+)-type amino acid transporter 1
CAT1Cationic amino acid transporter 1
CAT2Cationic amino acid transporter 2
CKDChronic kidney disease
CVDCardiovascular disease
DDAH1Dimethylaminohydrolase 1
eGFREstimated glomerular filtration rate
HPAHuman Protein Atlas
KTAKidney Tissue Atlas
MATE1Multidrug and toxin extrusion protein 1
NONitric oxide
NOSNitric oxide synthase
OATP4C1Organic anion transporting polypeptide 4C1
OCT2Organic cation transporter 2
scRNASingle-cell RNA
SDMASymmetric dimethylarginine
SNPSingle nucleotide polymorphisms
y+LAT1y+L amino acid transporter 1
y+LAT2y+L amino acid transporter 2

References

  1. Zoccali, C.; Bode-Böger, S.M.; Mallamaci, F.; Benedetto, F.A.; Tripepi, G.; Malatino, L.S.; Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frölich, J.C.; et al. Plasma Concentration of Asymmetrical Dimethylarginine and Mortality in Patients with End-Stage Renal Disease: A Prospective Study. Lancet 2001, 358, 2113–2117. [Google Scholar] [CrossRef]
  2. Ravani, P.; Maas, R.; Malberti, F.; Pecchini, P.; Mieth, M.; Quinn, R.; Tripepi, G.; Mallamaci, F.; Zoccali, C. Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients. PLoS ONE 2013, 8, e72694. [Google Scholar] [CrossRef] [PubMed]
  3. Schlesinger, S.; Sonntag, S.R.; Lieb, W.; Maas, R. Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS ONE 2016, 11, e0165811. [Google Scholar] [CrossRef] [PubMed]
  4. Au, A.Y.M.; Mantik, K.; Bahadory, F.; Stathakis, P.; Guiney, H.; Erlich, J.; Walker, R.; Poulton, R.; Horvath, A.R.; Endre, Z.H. Plasma Arginine Metabolites in Health and Chronic Kidney Disease. Nephrol. Dial. Transplant. 2023, 38, 2767–2775. [Google Scholar] [CrossRef] [PubMed]
  5. Vallance, P.; Leone, A.; Moncada, S.; Calver, A.; Collier, J. Accumulation of an Endogenous Inhibitor of Nitric Oxide Synthesis in Chronic Renal Failure. Lancet 1992, 339, 572–575. [Google Scholar] [CrossRef]
  6. Tsikas, D.; Bollenbach, A.; Hanff, E.; Kayacelebi, A.A. Asymmetric Dimethylarginine (ADMA), Symmetric Dimethylarginine (SDMA) and Homoarginine (hArg): The ADMA, SDMA and hArg Paradoxes. Cardiovasc. Diabetol. 2018, 17, 1. [Google Scholar] [CrossRef]
  7. März, W.; Meinitzer, A.; Drechsler, C.; Pilz, S.; Krane, V.; Kleber, M.E.; Fischer, J.; Winkelmann, B.R.; Böhm, B.O.; Ritz, E.; et al. Homoarginine, Cardiovascular Risk, and Mortality. Circulation 2010, 122, 967–975. [Google Scholar] [CrossRef]
  8. Palmer, R.M.; Ashton, D.; Moncada, S. Vascular Endothelial Cells Synthesize Nitric Oxide from L-Arginine. Nature 1988, 333, 664–666. [Google Scholar] [CrossRef]
  9. Achan, V.; Broadhead, M.; Malaki, M.; Whitley, G.; Leiper, J.; MacAllister, R.; Vallance, P. Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 1455–1459. [Google Scholar] [CrossRef]
  10. Kittel, A.; Maas, R. Pharmacology and Clinical Pharmacology of Methylarginines Used as Inhibitors of Nitric Oxide Synthases. Curr. Pharm. Des. 2014, 20, 3530–3547. [Google Scholar] [CrossRef]
  11. Closs, E.I.; Basha, F.Z.; Habermeier, A.; Förstermann, U. Interference of L-Arginine Analogues with L-Arginine Transport Mediated by the y+carrier hCAT-2B. Nitric Oxide 1997, 1, 65–73. [Google Scholar] [CrossRef]
  12. Strobel, J.; Mieth, M.; Endreß, B.; Auge, D.; König, J.; Fromm, M.F.; Maas, R. Interaction of the Cardiovascular Risk Marker Asymmetric Dimethylarginine (ADMA) with the Human Cationic Amino Acid Transporter 1 (CAT1). J. Mol. Cell. Cardiol. 2012, 53, 392–400. [Google Scholar] [CrossRef] [PubMed]
  13. Drechsler, C.; Kollerits, B.; Meinitzer, A.; März, W.; Ritz, E.; König, P.; Neyer, U.; Pilz, S.; Wanner, C.; Kronenberg, F.; et al. Homoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study. PLoS ONE 2013, 8, e63560. [Google Scholar] [CrossRef] [PubMed]
  14. Pilz, S.; Teerlink, T.; Scheffer, P.G.; Meinitzer, A.; Rutters, F.; Tomaschitz, A.; Drechsler, C.; Kienreich, K.; Nijpels, G.; Stehouwer, C.D.A.; et al. Homoarginine and Mortality in an Older Population: The Hoorn Study. Eur. J. Clin. Investig. 2014, 44, 200–208. [Google Scholar] [CrossRef] [PubMed]
  15. Tomaschitz, A.; Meinitzer, A.; Pilz, S.; Rus-Machan, J.; Genser, B.; Drechsler, C.; Grammer, T.; Krane, V.; Ritz, E.; Kleber, M.E.; et al. Homoarginine, Kidney Function and Cardiovascular Mortality Risk. Nephrol. Dial. Transplant. 2014, 29, 663–671. [Google Scholar] [CrossRef]
  16. Gansevoort, R.T.; Correa-Rotter, R.; Hemmelgarn, B.R.; Jafar, T.H.; Heerspink, H.J.L.; Mann, J.F.; Matsushita, K.; Wen, C.P. Chronic Kidney Disease and Cardiovascular Risk: Epidemiology, Mechanisms, and Prevention. Lancet 2013, 382, 339–352. [Google Scholar] [CrossRef]
  17. Gessner, A.; Gemeinhardt, A.; Bosch, A.; Kannenkeril, D.; Staerk, C.; Mayr, A.; Fromm, M.F.; Schmieder, R.E.; Maas, R. Effects of Treatment with SGLT-2 Inhibitors on Arginine-Related Cardiovascular and Renal Biomarkers. Cardiovasc. Diabetol. 2022, 21, 4. [Google Scholar] [CrossRef]
  18. Cox, B.; Cameron, J. Homoarginine in Cystinuria. Clin. Sci. Mol. Med. 1974, 46, 173–182. [Google Scholar] [CrossRef]
  19. Torremans, A.; Marescau, B.; Vanholder, R.; De Smet, R.; Billiouw, J.-M.; De Deyn, P. The Low Nanomolar Levels of NG-Monomethylarginine in Serum and Urine of Patients with Chronic Renal Insufficiency Are Not Significantly Different from Control Levels. Amino Acids 2003, 24, 375–381. [Google Scholar] [CrossRef]
  20. Kurko, J.; Tringham, M.; Tanner, L.; Näntö-Salonen, K.; Vähä-Mäkilä, M.; Nygren, H.; Pöhö, P.; Lietzen, N.; Mattila, I.; Olkku, A.; et al. Imbalance of Plasma Amino Acids, Metabolites and Lipids in Patients with Lysinuric Protein Intolerance (LPI). Metabolism 2016, 65, 1361–1375. [Google Scholar] [CrossRef]
  21. Brosnan, M.E.; Brosnan, J.T. Renal Arginine Metabolism. J. Nutr. 2004, 134, 2791S–2795S. [Google Scholar] [CrossRef] [PubMed]
  22. Pilz, S.; Meinitzer, A.; Gaksch, M.; Grübler, M.; Verheyen, N.; Drechsler, C.; ó Hartaigh, B.; Lang, F.; Alesutan, I.; Voelkl, J.; et al. Homoarginine in the Renal and Cardiovascular Systems. Amino Acids 2015, 47, 1703–1713. [Google Scholar] [CrossRef] [PubMed]
  23. Schepers, E.; Speer, T.; Bode-Böger, S.M.; Fliser, D.; Kielstein, J.T. Dimethylarginines ADMA and SDMA: The Real Water-Soluble Small Toxins? Semin. Nephrol. 2014, 34, 97–105. [Google Scholar] [CrossRef] [PubMed]
  24. Rosner, M.H.; Reis, T.; Husain-Syed, F.; Vanholder, R.; Hutchison, C.; Stenvinkel, P.; Blankestijn, P.J.; Cozzolino, M.; Juillard, L.; Kashani, K.; et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin. J. Am. Soc. Nephrol. 2021, 16, 1918–1928. [Google Scholar] [CrossRef]
  25. Ronden, R.A.; Houben, A.J.; Teerlink, T.; Bakker, J.A.; Bierau, J.; Stehouwer, C.D.; De Leeuw, P.W.; Kroon, A.A. Reduced Renal Plasma Clearance Does Not Explain Increased Plasma Asymmetric Dimethylarginine in Hypertensive Subjects with Mild to Moderate Renal Insufficiency. Am. J. Physiol. Ren. Physiol. 2012, 303, F149–F156. [Google Scholar] [CrossRef]
  26. Al Banchaabouchi, M.; Marescau, B.; Possemiers, I.; D’Hooge, R.; Levillain, O.; De Deyn, P.P. NG,NG-Dimethylarginine and NG,N’G-Dimethylarginine in Renal Insufficiency. Pflügers Arch.—Eur. J. Physiol. 2000, 439, 524–531. [Google Scholar] [CrossRef]
  27. Banjarnahor, S.; Scherpinski, L.A.; Keller, M.; König, J.; Maas, R. Differential Uptake of Arginine Derivatives by the Human Heteromeric Amino Acid Transporter b0,+AT-rBAT (SLC7A9-SLC3A1). Naunyn-Schmiedeberg’s Arch. Pharmacol. 2024, 398, 4419–4434. [Google Scholar] [CrossRef]
  28. Strobel, J.; Müller, F.; Zolk, O.; Endreß, B.; König, J.; Fromm, M.F.; Maas, R. Transport of Asymmetric Dimethylarginine (ADMA) by Cationic Amino Acid Transporter 2 (CAT2), Organic Cation Transporter 2 (OCT2) and Multidrug and Toxin Extrusion Protein 1 (MATE1). Amino Acids 2013, 45, 989–1002. [Google Scholar] [CrossRef]
  29. Taghikhani, E.; Maas, R.; Fromm, M.F.; König, J. The Renal Transport Protein OATP4C1 Mediates Uptake of the Uremic Toxin Asymmetric Dimethylarginine (ADMA) and Efflux of Cardioprotective L-Homoarginine. PLoS ONE 2019, 14, e0213747. [Google Scholar] [CrossRef]
  30. Banjarnahor, S.; Rodionov, R.N.; König, J.; Maas, R. Transport of L-Arginine Related Cardiovascular Risk Markers. J. Clin. Med. 2020, 9, 3975. [Google Scholar] [CrossRef]
  31. Chafai, A.; Fromm, M.F.; König, J.; Maas, R. The Prognostic Biomarker L-Homoarginine Is a Substrate of the Cationic Amino Acid Transporters CAT1, CAT2A and CAT2B. Sci. Rep. 2017, 7, 4767. [Google Scholar] [CrossRef] [PubMed]
  32. Verrey, F.; Meier, C.; Rossier, G.; Kühn, L.C. Glycoprotein-Associated Amino Acid Exchangers: Broadening the Range of Transport Specificity. Pflügers Arch. 2000, 440, 503–512. [Google Scholar] [CrossRef] [PubMed]
  33. Closs, E.I.; Simon, A.; Vékony, N.; Rotmann, A. Plasma Membrane Transporters for Arginine. J. Nutr. 2004, 134, 2752S–2759S. [Google Scholar] [CrossRef] [PubMed]
  34. Morris, S.M., Jr. Arginine Metabolism Revisited. J. Nutr. 2016, 146, 2579S–2586S. [Google Scholar] [CrossRef] [PubMed]
  35. Windmueller, H.G.; Spaeth, A.E. Source and Fate of Circulating Citrulline. Am. J. Physiol.-Endocrinol. Metab. 1981, 241, E473–E480. [Google Scholar] [CrossRef]
  36. Kielstein, J.T.; Böger, R.H.; Bode-Böger, S.M.; Frölich, J.C.; Haller, H.; Ritz, E.; Fliser, D. Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease. J. Am. Soc. Nephrol. 2002, 13, 170–176. [Google Scholar] [CrossRef]
  37. Bouby, N.; Hassler, C.; Parvy, P.; Bankir, L. Renal Synthesis of Arginine in Chronic Renal Failure: In Vivo and in Vitro Studies in Rats with 5/6 Nephrectomy. Kidney Int. 1993, 44, 676–683. [Google Scholar] [CrossRef]
  38. Baylis, C. Nitric Oxide Deficiency in Chronic Kidney Disease. Am. J. Physiol.-Ren. Physiol. 2008, 294, F1–F9. [Google Scholar] [CrossRef]
  39. Schmidt, R.J.; Baylis, C. Total Nitric Oxide Production Is Low in Patients with Chronic Renal Disease. Kidney Int. 2000, 58, 1261–1266. [Google Scholar] [CrossRef]
  40. Lau, T.; Owen, W.; Yu, Y.M.; Noviski, N.; Lyons, J.; Zurakowski, D.; Tsay, R.; Ajami, A.; Young, V.R.; Castillo, L. Arginine, Citrulline, and Nitric Oxide Metabolism in End-Stage Renal Disease Patients. J. Clin. Investig. 2000, 105, 1217–1225. [Google Scholar] [CrossRef]
  41. Bredt, D.S.; Snyder, S.H. Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme. Proc. Natl. Acad. Sci. USA 1990, 87, 682–685. [Google Scholar] [CrossRef]
  42. Moali, C.; Boucher, J.-L.; Sari, M.-A.; Stuehr, D.J.; Mansuy, D. Substrate Specificity of NO Synthases: Detailed Comparison of L-Arginine, Homo-L-Arginine, Their Nω-Hydroxy Derivatives, and Nω-Hydroxynor-L-Arginine. Biochemistry 1998, 37, 10453–10460. [Google Scholar] [CrossRef] [PubMed]
  43. Evans, R.W.; Fernstrom, J.D.; Thompson, J.; Morris, S.M., Jr.; Kuller, L.H. Biochemical Responses of Healthy Subjects during Dietary Supplementation with L-Arginine. J. Nutr. Biochem. 2004, 15, 534–539. [Google Scholar] [CrossRef] [PubMed]
  44. Dong, J.-Y.; Qin, L.-Q.; Zhang, Z.; Zhao, Y.; Wang, J.; Arigoni, F.; Zhang, W. Effect of Oral L-Arginine Supplementation on Blood Pressure: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials. Am. Heart J. 2011, 162, 959–965. [Google Scholar] [CrossRef] [PubMed]
  45. Teunissen-Beekman, K.F.; van Baak, M.A. The Role of Dietary Protein in Blood Pressure Regulation. Curr. Opin. Lipidol. 2013, 24, 65–70. [Google Scholar] [CrossRef]
  46. Appel, L.J. The Effects of Protein Intake on Blood Pressure and Cardiovascular Disease. Curr. Opin. Lipidol. 2003, 14, 55–59. [Google Scholar] [CrossRef]
  47. Schulman, S.P.; Becker, L.C.; Kass, D.A.; Champion, H.C.; Terrin, M.L.; Forman, S.; Ernst, K.V.; Kelemen, M.D.; Townsend, S.N.; Capriotti, A.; et al. L-Arginine Therapy in Acute Myocardial Infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial. JAMA 2006, 295, 58–64. [Google Scholar] [CrossRef]
  48. Schwedhelm, E.; Maas, R.; Freese, R.; Jung, D.; Lukacs, Z.; Jambrecina, A.; Spickler, W.; Schulze, F.; Böger, R.H. Pharmacokinetic and Pharmacodynamic Properties of Oral L-Citrulline and L-Arginine: Impact on Nitric Oxide Metabolism. Br. J. Clin. Pharmacol. 2008, 65, 51–59. [Google Scholar] [CrossRef]
  49. Choe, C.; Atzler, D.; Wild, P.S.; Carter, A.M.; Böger, R.H.; Ojeda, F.; Simova, O.; Stockebrand, M.; Lackner, K.; Nabuurs, C.; et al. Homoarginine Levels Are Regulated by L-Arginine: Glycine Amidinotransferase and Affect Stroke Outcome: Results from Human and Murine Studies. Circulation 2013, 128, 1451–1461. [Google Scholar] [CrossRef]
  50. Maas, R.; Tan-Andreesen, J.; Schwedhelm, E.; Schulze, F.; Böger, R.H. A Stable-Isotope Based Technique for the Determination of Dimethylarginine Dimethylaminohydrolase (DDAH) Activity in Mouse Tissue. J. Chromatogr. B 2007, 851, 220–228. [Google Scholar] [CrossRef]
  51. Shirakawa, T.; Kako, K.; Shimada, T.; Nagashima, Y.; Nakamura, A.; Ishida, J.; Fukamizu, A. Production of Free Methylarginines via the Proteasome and Autophagy Pathways in Cultured Cells. Mol. Med. Rep. 2011, 4, 615–620. [Google Scholar] [CrossRef]
  52. Kimoto, M.; Whitley, G.S.J.; Tsuji, H.; Ogawa, T. Detection of NG, NG-Dimethylarginine Dimethylaminohydrolase in Human Tissues Using a Monoclonal Antibody. J. Biochem. 1995, 117, 237–238. [Google Scholar] [CrossRef] [PubMed]
  53. Caplin, B.; Wang, Z.; Slaviero, A.; Tomlinson, J.; Dowsett, L.; Delahaye, M.; Salama, A.; The International Consortium for Blood Pressure Genome-Wide Association Studies; Wheeler, D.C.; Leiper, J. Alanine-Glyoxylate Aminotransferase-2 Metabolizes Endogenous Methylarginines, Regulates NO, and Controls Blood Pressure. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2892–2900. [Google Scholar] [CrossRef] [PubMed]
  54. Jarzebska, N.; Mangoni, A.A.; Martens-Lobenhoffer, J.; Bode-Böger, S.M.; Rodionov, R.N. The Second Life of Methylarginines as Cardiovascular Targets. Int. J. Mol. Sci. 2019, 20, 4592. [Google Scholar] [CrossRef] [PubMed]
  55. Oliva-Damaso, E.; Oliva-Damaso, N.; Rodriguez-Esparragon, F.; Payan, J.; Baamonde-Laborda, E.; Gonzalez-Cabrera, F.; Santana-Estupiñan, R.; Rodriguez-Perez, J.C. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach. Int. J. Mol. Sci. 2019, 20, 3668. [Google Scholar] [CrossRef]
  56. Carello, K.A.; Whitesall, S.E.; Lloyd, M.C.; Billecke, S.S.; D’Alecy, L.G. Asymmetrical Dimethylarginine Plasma Clearance Persists after Acute Total Nephrectomy in Rats. Am. J. Physiol.-Heart Circ. Physiol. 2006, 290, H209–H216. [Google Scholar] [CrossRef]
  57. Lluch, P.; Segarra, G.; Medina, P. Asymmetric Dimethylarginine as a Mediator of Vascular Dysfunction in Cirrhosis. World J. Gastroenterol. WJG 2015, 21, 9466–9475. [Google Scholar] [CrossRef]
  58. Castillo, L.; Ajami, A.; Branch, S.; Chapman, T.; Yu, Y.-M.; Burke, J.; Young, V. Plasma Arginine Kinetics in Adult Man: Response to an Arginine-Free Diet. Metabolism 1994, 43, 114–122. [Google Scholar] [CrossRef]
  59. Castillo, L.; Beaumier, L.; Ajami, A.M.; Young, V.R. Whole Body Nitric Oxide Synthesis in Healthy Men Determined from [15N] Arginine-to-[15N] Citrulline Labeling. Proc. Natl. Acad. Sci. USA 1996, 93, 11460–11465. [Google Scholar] [CrossRef]
  60. Böger, R.H. The Pharmacodynamics of L-Arginine. J. Nutr. 2007, 137, 1650S–1655S. [Google Scholar] [CrossRef]
  61. Rodionov, R.N.; Oppici, E.; Martens-Lobenhoffer, J.; Jarzebska, N.; Brilloff, S.; Burdin, D.; Demyanov, A.; Kolouschek, A.; Leiper, J.; Maas, R.; et al. A Novel Pathway for Metabolism of the Cardiovascular Risk Factor Homoarginine by Alanine: Glyoxylate Aminotransferase 2. Sci. Rep. 2016, 6, 35277. [Google Scholar] [CrossRef] [PubMed]
  62. Bollenbach, A.; Cordts, K.; Hanff, E.; Atzler, D.; Choe, C.; Schwedhelm, E.; Tsikas, D. Evidence by GC-MS That Lysine Is an Arginase-Catalyzed Metabolite of Homoarginine in Vitro and in Vivo in Humans. Anal. Biochem. 2019, 577, 59–66. [Google Scholar] [CrossRef] [PubMed]
  63. McMenamy, R.H.; Lund, C.C.; Oncley, J.L. Unbound Amino Acid Concentrations in Human Blood Plasmas. J. Clin. Investig. 1957, 36, 1672–1679. [Google Scholar] [CrossRef] [PubMed]
  64. Said, M.Y.; Douwes, R.M.; van Londen, M.; Minović, I.; Frenay, A.-R.; de Borst, M.H.; van den Berg, E.; Heiner-Fokkema, M.R.; Kayacelebi, A.A.; Bollenbach, A.; et al. Effect of Renal Function on Homeostasis of Asymmetric Dimethylarginine (ADMA): Studies in Donors and Recipients of Renal Transplants. Amino Acids 2019, 51, 565–575. [Google Scholar] [CrossRef]
  65. Servillo, L.; Giovane, A.; D’Onofrio, N.; Casale, R.; Cautela, D.; Castaldo, D.; Balestrieri, M.L. Determination of Homoarginine, Arginine, NMMA, ADMA, and SDMA in Biological Samples by HPLC-ESI-Mass Spectrometry. Int. J. Mol. Sci. 2013, 14, 20131–20138. [Google Scholar] [CrossRef]
  66. Akyurek, F.; Celik, G.; Ozturk, B. Predictive Role of Methylarginines in Renal Failure. Ann. Med. Res. 2020, 27, 2129–2133. [Google Scholar] [CrossRef]
  67. Lluch, P.; Torondel, B.; Medina, P.; Segarra, G.; Del Olmo, J.A.; Serra, M.A.; Rodrigo, J.M. Plasma Concentrations of Nitric Oxide and Asymmetric Dimethylarginine in Human Alcoholic Cirrhosis. J. Hepatol. 2004, 41, 55–59. [Google Scholar] [CrossRef]
  68. Schwedhelm, E.; Wallaschofski, H.; Atzler, D.; Dörr, M.; Nauck, M.; Völker, U.; Kroemer, H.K.; Völzke, H.; Böger, R.H.; Friedrich, N. Incidence of All-Cause and Cardiovascular Mortality Predicted by Symmetric Dimethylarginine in the Population-Based Study of Health in Pomerania. PLoS ONE 2014, 9, e96875. [Google Scholar] [CrossRef]
  69. Kato, T.; Sano, M.; Mizutani, N. Homocitrullinuria and Homoargininuria in Lysinuric Protein Intolerance. J. Inherit. Metab. Dis. 1989, 12, 157–161. [Google Scholar] [CrossRef]
  70. Atzler, D.; Mieth, M.; Maas, R.; Böger, R.H.; Schwedhelm, E. Stable Isotope Dilution Assay for Liquid Chromatography–Tandem Mass Spectrometric Determination of L-Homoarginine in Human Plasma. J. Chromatogr. B 2011, 879, 2294–2298. [Google Scholar] [CrossRef]
  71. May, M.; Batkai, S.; Zörner, A.A.; Tsikas, D.; Jordan, J.; Engeli, S. Clinical Evaluation of Extracellular ADMA Concentrations in Human Blood and Adipose Tissue. Int. J. Mol. Sci. 2014, 15, 1189–1200. [Google Scholar] [CrossRef]
  72. Nijveldt, R.; Teerlink, T.; Van Der Hoven, B.; Siroen, M.; Kuik, D.; Rauwerda, J.; Van Leeuwen, P. Asymmetrical Dimethylarginine (ADMA) in Critically Ill Patients: High Plasma ADMA Concentration Is an Independent Risk Factor of ICU Mortality. Crit. Care 2003, 7, 23–30. [Google Scholar] [CrossRef]
  73. Teerlink, T. HPLC Analysis of ADMA and Other Methylated L-Arginine Analogs in Biological Fluids. J. Chromatogr. B 2007, 851, 21–29. [Google Scholar] [CrossRef] [PubMed]
  74. Emrich, I.E.; Zawada, A.M.; Martens-Lobenhoffer, J.; Fliser, D.; Wagenpfeil, S.; Heine, G.H.; Bode-Böger, S.M. Symmetric Dimethylarginine (SDMA) Outperforms Asymmetric Dimethylarginine (ADMA) and Other Methylarginines as Predictor of Renal and Cardiovascular Outcome in Non-Dialysis Chronic Kidney Disease. Clin. Res. Cardiol. 2018, 107, 201–213. [Google Scholar] [CrossRef] [PubMed]
  75. Schepers, E.; Glorieux, G.; Dhondt, A.; Leybaert, L.; Vanholder, R. Role of Symmetric Dimethylarginine in Vascular Damage by Increasing ROS via Store-Operated Calcium Influx in Monocytes. Nephrol. Dial. Transplant. 2009, 24, 1429–1435. [Google Scholar] [CrossRef]
  76. Schepers, E.; Barreto, D.V.; Liabeuf, S.; Glorieux, G.; Eloot, S.; Barreto, F.C.; Massy, Z.; Vanholder, R. Symmetric Dimethylarginine as a Proinflammatory Agent in Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. CJASN 2011, 6, 2374–2383. [Google Scholar] [CrossRef]
  77. Riddell, A.; Flynn, A.; Bergugnat, H.; Dowsett, L.B.; Miller, A.A. SDMA as a Marker and Mediator in Cerebrovascular Disease. Clin. Sci. 2024, 138, 1305–1323. [Google Scholar] [CrossRef]
  78. Surrer, D.B.; Fromm, M.F.; Maas, R.; König, J. L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact. Metabolites 2022, 12, 273. [Google Scholar] [CrossRef]
  79. Lüneburg, N.; Lieb, W.; Zeller, T.; Chen, M.-H.; Maas, R.; Carter, A.M.; Xanthakis, V.; Glazer, N.L.; Schwedhelm, E.; Seshadri, S.; et al. Genome-Wide Association Study of L-Arginine and Dimethylarginines Reveals Novel Metabolic Pathway for Symmetric Dimethylarginine. Circ. Cardiovasc. Genet. 2014, 7, 864–872. [Google Scholar] [CrossRef]
  80. Marescau, B.; Nagels, G.; Possemiers, I.; De Broe, M.E.; Becaus, I.; Billiouw, J.-M.; Lornoy, W.; De Deyn, P.P. Guanidino Compounds in Serum and Urine of Nondialyzed Patients with Chronic Renal Insufficiency. Metabolism 1997, 46, 1024–1031. [Google Scholar] [CrossRef]
  81. Veldink, H.; Faulhaber-Walter, R.; Park, J.-K.; Martens-Lobenhoffer, J.; Bode-Böger, S.; Schuett, H.; Haghikia, A.; Hilfiker-Kleiner, D.; Kielstein, J.T. Effects of Chronic SDMA Infusion on Glomerular Filtration Rate, Blood Pressure, Myocardial Function and Renal Histology in C57BL6/J Mice. Nephrol. Dial. Transplant. 2013, 28, 1434–1439. [Google Scholar] [CrossRef] [PubMed]
  82. Bröer, S.; Fairweather, S.J. Amino Acid Transport across the Mammalian Intestine. Compr. Physiol. 2018, 9, 343–373. [Google Scholar] [CrossRef] [PubMed]
  83. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A Human Transporter Protein That Mediates the Final Excretion Step for Toxic Organic Cations. Proc. Natl. Acad. Sci. USA 2005, 102, 17923–17928. [Google Scholar] [CrossRef]
  84. Yoshimoto, T.; Yoshimoto, E.; Meruelo, D. Molecular Cloning and Characterization of a Novel Human Gene Homologous to the Murine Ecotropic Retroviral Receptor. Virology 1991, 185, 10–17. [Google Scholar] [CrossRef]
  85. Wu, F.; Cholewa, B.; Mattson, D.L. Characterization of L-Arginine Transporters in Rat Renal Inner Medullary Collecting Duct. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278, R1506–R1512. [Google Scholar] [CrossRef]
  86. Burger-Kentischer, A.; Müller, E.; Klein, H.G.; Schober, A.; Neuhofer, W.; Beck, F.X. Cationic Amino Acid Transporter mRNA Expression in Rat Kidney and Liver. Kidney Int. Suppl. 1998, 67, S136–S138. [Google Scholar] [CrossRef]
  87. Bröer, A.; Wagner, C.A.; Lang, F.; Bröer, S. The Heterodimeric Amino Acid Transporter 4F2hc/y+LAT2 Mediates Arginine Efflux in Exchange with Glutamine. Biochem. J. 2000, 349, 787–795. [Google Scholar] [CrossRef]
  88. Torrents, D.; Mykkänen, J.; Pineda, M.; Feliubadaló, L.; Estévez, R.; de Cid, R.; Sanjurjo, P.; Zorzano, A.; Nunes, V.; Huoponen, K.; et al. Identification of SLC7A7, Encoding y+LAT-1, as the Lysinuric Protein Intolerance Gene. Nat. Genet. 1999, 21, 293–296. [Google Scholar] [CrossRef]
  89. Mikkaichi, T.; Suzuki, T.; Onogawa, T.; Tanemoto, M.; Mizutamari, H.; Okada, M.; Chaki, T.; Masuda, S.; Tokui, T.; Eto, N.; et al. Isolation and Characterization of a Digoxin Transporter and Its Rat Homologue Expressed in the Kidney. Proc. Natl. Acad. Sci. USA 2004, 101, 3569–3574. [Google Scholar] [CrossRef]
  90. Urakami, Y.; Akazawa, M.; Saito, H.; Okuda, M.; Inui, K. cDNA Cloning, Functional Characterization, and Tissue Distribution of an Alternatively Spliced Variant of Organic Cation Transporter hOCT2 Predominantly Expressed in the Human Kidney. J. Am. Soc. Nephrol. 2002, 13, 1703–1710. [Google Scholar] [CrossRef]
  91. Gorboulev, V.; Ulzheimer, J.C.; Akhoundova, A.; Ulzheimer-Teuber, I.; Karbach, U.; Quester, S.; Baumann, C.; Lang, F.; Busch, A.E.; Koepsell, H. Cloning and Characterization of Two Human Polyspecific Organic Cation Transporters. DNA Cell Biol. 1997, 16, 871–881. [Google Scholar] [CrossRef]
  92. Karlsson, M.; Zhang, C.; Méar, L.; Zhong, W.; Digre, A.; Katona, B.; Sjöstedt, E.; Butler, L.; Odeberg, J.; Dusart, P.; et al. A Single–Cell Type Transcriptomics Map of Human Tissues. Sci. Adv. 2021, 7, eabh2169. [Google Scholar] [CrossRef]
  93. Kidney Precision Medicine Project (KPMP). Available online: https://www.kpmp.org (accessed on 4 March 2025).
  94. Human Protein Atlas V24.0-Single Cell Type—SLC7A9. Available online: https://www.proteinatlas.org/ENSG00000021488-SLC7A9/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  95. Human Protein Atlas V24.0-Single Cell Type—SLC47A1. Available online: https://www.proteinatlas.org/ENSG00000142494-SLC47A1/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  96. Human Protein Atlas V24.0-Single Cell Type—SLC3A2. Available online: https://www.proteinatlas.org/ENSG00000168003-SLC3A2/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  97. Human Protein Atlas V24.0-Single Cell Type—SLC7A1. Available online: https://www.proteinatlas.org/ENSG00000139514-SLC7A1/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  98. Human Protein Atlas V24.0-Single Cell Type—SLC7A2. Available online: https://www.proteinatlas.org/ENSG00000003989-SLC7A2/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  99. Human Protein Atlas V24.0-Single Cell Type—SLC7A6. Available online: https://www.proteinatlas.org/ENSG00000103064-SLC7A6/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  100. Human Protein Atlas V24.0-Single Cell Type—SLC7A7. Available online: https://www.proteinatlas.org/ENSG00000155465-SLC7A7/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  101. Human Protein Atlas V24.0-Single Cell Type—SLC22A2. Available online: https://www.proteinatlas.org/ENSG00000112499-SLC22A2/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  102. Human Protein Atlas V24.0-Single Cell Type—SLCO4C1. Available online: https://www.proteinatlas.org/ENSG00000173930-SLCO4C1/single+cell#single_cell_type_summary (accessed on 4 March 2025).
  103. Lake, B.B.; Menon, R.; Winfree, S.; Hu, Q.; Melo Ferreira, R.; Kalhor, K.; Barwinska, D.; Otto, E.A.; Ferkowicz, M.; Diep, D.; et al. An Atlas of Healthy and Injured Cell States and Niches in the Human Kidney. Nature 2023, 619, 585–594. [Google Scholar] [CrossRef]
  104. Makrides, V.; Camargo, S.M.R.; Verrey, F. Transport of Amino Acids in the Kidney. Compr. Physiol. 2014, 4, 367–403. [Google Scholar] [CrossRef]
  105. Kakoki, M.; Kim, H.-S.; Arendshorst, W.J.; Mattson, D.L. L-Arginine Uptake Affects Nitric Oxide Production and Blood Flow in the Renal Medulla. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2004, 287, R1478–R1485. [Google Scholar] [CrossRef]
  106. Kakoki, M.; Wang, W.; Mattson, D.L. Cationic Amino Acid Transport in the Renal Medulla and Blood Pressure Regulation. Hypertension 2002, 39, 287–292. [Google Scholar] [CrossRef] [PubMed]
  107. Estévez, R.; Camps, M.; Rojas, A.M.; Testar, X.; Devîs, R.; Hediger, M.A.; Zorzano, A.; Palacín, M. The Amino Acid Transport System y+L/4F2hc Is a Heteromultimeric Complex. FASEB J. 1998, 12, 1319–1329. [Google Scholar] [CrossRef] [PubMed]
  108. Grahammer, F.; Ramakrishnan, S.K.; Rinschen, M.M.; Larionov, A.A.; Syed, M.; Khatib, H.; Roerden, M.; Sass, J.O.; Helmstaedter, M.; Osenberg, D.; et al. mTOR Regulates Endocytosis and Nutrient Transport in Proximal Tubular Cells. J. Am. Soc. Nephrol. 2017, 28, 230–241. [Google Scholar] [CrossRef] [PubMed]
  109. Kanai, Y.; Fukasawa, Y.; Cha, S.H.; Segawa, H.; Chairoungdua, A.; Kim, D.K.; Matsuo, H.; Kim, J.Y.; Miyamoto, K.; Takeda, E.; et al. Transport Properties of a System y+L Neutral and Basic Amino Acid Transporter. J. Biol. Chem. 2000, 275, 20787–20793. [Google Scholar] [CrossRef]
  110. Fotiadis, D.; Kanai, Y.; Palacín, M. The SLC3 and SLC7 Families of Amino Acid Transporters. Mol. Asp. Med. 2013, 34, 139–158. [Google Scholar] [CrossRef]
  111. Rotoli, B.M.; Barilli, A.; Visigalli, R.; Ferrari, F.; Dall’Asta, V. y+LAT1 and y+LAT2 Contribution to Arginine Uptake in Different Human Cell Models: Implications in the Pathophysiology of Lysinuric Protein Intolerance. J. Cell. Mol. Med. 2020, 24, 921–929. [Google Scholar] [CrossRef]
  112. Closs, E.I.; Ostad, M.A.; Simon, A.; Warnholtz, A.; Jabs, A.; Habermeier, A.; Daiber, A.; Förstermann, U.; Münzel, T. Impairment of the Extrusion Transporter for Asymmetric Dimethyl-L-Arginine: A Novel Mechanism Underlying Vasospastic Angina. Biochem. Biophys. Res. Commun. 2012, 423, 218–223. [Google Scholar] [CrossRef]
  113. Bauch, C.; Verrey, F. Apical Heterodimeric Cystine and Cationic Amino Acid Transporter Expressed in MDCK Cells. Am. J. Physiol.-Ren. Physiol. 2002, 283, F181–F189. [Google Scholar] [CrossRef]
  114. Toyohara, T.; Suzuki, T.; Morimoto, R.; Akiyama, Y.; Souma, T.; Shiwaku, H.O.; Takeuchi, Y.; Mishima, E.; Abe, M.; Tanemoto, M.; et al. SLCO4C1 Transporter Eliminates Uremic Toxins and Attenuates Hypertension and Renal Inflammation. J. Am. Soc. Nephrol. 2009, 20, 2546–2555. [Google Scholar] [CrossRef] [PubMed]
  115. Scherpinski, L.A.; Fromm, M.F.; Maas, R.; König, J. Transport of the Uremic Toxin Symmetric Dimethylarginine (SDMA) by Renal Transport Proteins. Amino Acids 2025, 57, 34. [Google Scholar] [CrossRef] [PubMed]
  116. Kamada, Y.; Nagaretani, H.; Tamura, S.; Ohama, T.; Maruyama, T.; Hiraoka, H.; Yamashita, S.; Yamada, A.; Kiso, S.; Inui, Y.; et al. Vascular Endothelial Dysfunction Resulting from L-Arginine Deficiency in a Patient with Lysinuric Protein Intolerance. J. Clin. Investig. 2001, 108, 717–724. [Google Scholar] [CrossRef] [PubMed]
  117. Kayanoki, Y.; Kawata, S.; Yamasaki, E.; Kiso, S.; Inoue, S.; Tamura, S.; Taniguchi, N.; Matsuzawa, Y. Reduced Nitric Oxide Production by L-Arginine Deficiency in Lysinuric Protein Intolerance Exacerbates Intravascular Coagulation. Metabolism 1999, 48, 1136–1140. [Google Scholar] [CrossRef]
  118. Fernández, E.; Jiménez-Vidal, M.; Calvo, M.; Zorzano, A.; Tebar, F.; Palacín, M.; Chillarón, J. The Structural and Functional Units of Heteromeric Amino Acid Transporters: The Heavy Subunit rBAT Dictates Oligomerization of the Heteromeric Amino Acid Transporters. J. Biol. Chem. 2006, 281, 26552–26561. [Google Scholar] [CrossRef]
  119. Wagner, C.A.; Lang, F.; Bröer, S. Function and Structure of Heterodimeric Amino Acid Transporters. Am. J. Physiol.-Cell Physiol. 2001, 281, C1077–C1093. [Google Scholar] [CrossRef]
  120. Nagamori, S.; Wiriyasermkul, P.; Guarch, M.E.; Okuyama, H.; Nakagomi, S.; Tadagaki, K.; Nishinaka, Y.; Bodoy, S.; Takafuji, K.; Okuda, S.; et al. Novel Cystine Transporter in Renal Proximal Tubule Identified as a Missing Partner of Cystinuria-Related Plasma Membrane Protein rBAT/SLC3A1. Proc. Natl. Acad. Sci. USA 2016, 113, 775–780. [Google Scholar] [CrossRef]
  121. Fernández, E.; Carrascal, M.; Rousaud, F.; Abián, J.; Zorzano, A.; Palacín, M.; Chillarón, J. rBAT-b0,+AT Heterodimer Is the Main Apical Reabsorption System for Cystine in the Kidney. Am. J. Physiol.-Ren. Physiol. 2002, 283, F540–F548. [Google Scholar] [CrossRef] [PubMed]
  122. Pineda, M.; Wagner, C.A.; Bröer, A.; Stehberger, P.A.; Kaltenbach, S.; Gelpí, J.L.; Martin del Rio, R.; Zorzano, A.; Palacín, M.; Lang, F.; et al. Cystinuria-Specific rBAT (R365W) Mutation Reveals Two Translocation Pathways in the Amino Acid Transporter rBAT-b0,+AT. Biochem. J. 2004, 377, 665–674. [Google Scholar] [CrossRef] [PubMed]
  123. Yan, R.; Li, Y.; Shi, Y.; Zhou, J.; Lei, J.; Huang, J.; Zhou, Q. Cryo-EM Structure of the Human Heteromeric Amino Acid Transporter b0,+AT-rBAT. Sci. Adv. 2020, 6, eaay6379. [Google Scholar] [CrossRef] [PubMed]
  124. Yan, R.; Zhao, X.; Lei, J.; Zhou, Q. Structure of the Human LAT1–4F2hc Heteromeric Amino Acid Transporter Complex. Nature 2019, 568, 127–130. [Google Scholar] [CrossRef]
  125. Lee, Y.; Wiriyasermkul, P.; Jin, C.; Quan, L.; Ohgaki, R.; Okuda, S.; Kusakizako, T.; Nishizawa, T.; Oda, K.; Ishitani, R.; et al. Cryo-EM Structure of the Human L-Type Amino Acid Transporter 1 in Complex with Glycoprotein CD98hc. Nat. Struct. Mol. Biol. 2019, 26, 510–517. [Google Scholar] [CrossRef]
  126. Mizoguchi, K.; Cha, S.H.; Chairoungdua, A.; Kim, D.K.; Shigeta, Y.; Matsuo, H.; Fukushima, J.-I.; Awa, Y.; Akakura, K.; Goya, T.; et al. Human Cystinuria-Related Transporter: Localization and Functional Characterization. Kidney Int. 2001, 59, 1821–1833. [Google Scholar] [CrossRef]
  127. Reig, N.; Chillarón, J.; Bartoccioni, P.; Fernández, E.; Bendahan, A.; Zorzano, A.; Kanner, B.; Palacín, M.; Bertran, J. The Light Subunit of System bo,+ Is Fully Functional in the Absence of the Heavy Subunit. EMBO J. 2002, 21, 4906–4914. [Google Scholar] [CrossRef]
  128. Torras-Llort, M.; Torrents, D.; Soriano-Garcia, J.; Gelpi, J.; Estévez, R.; Ferrer, R.; Palacin, M.; Moreto, M. Sequential Amino Acid Exchange across b0,+-like System in Chicken Brush Border Jejunum. J. Membr. Biol. 2001, 180, 213–220. [Google Scholar] [CrossRef]
  129. Iuliano, I.; Iervolino, A.; Suzumoto, Y.; Shams, A.; Longobardi, C.; Capasso, G.; Perna, A.F.; Capolongo, G. Cystinuria: A Genetic and Molecular View. What Is Known about Animal Models and Cells. Kidney Blood Press. Res. 2025. [Google Scholar] [CrossRef]
  130. Strologo, L.D.; Pras, E.; Pontesilli, C.; Beccia, E.; Ricci-Barbini, V.; de Sanctis, L.; Ponzone, A.; Gallucci, M.; Bisceglia, L.; Zelante, L.; et al. Comparison between SLC3A1 and SLC7A9 Cystinuria Patients and Carriers: A Need for a New Classification. J. Am. Soc. Nephrol. 2002, 13, 2547–2553. [Google Scholar] [CrossRef]
  131. Brodehl, J. Isolated Cystinuria (without Lysin-, Ornithinand Argininuria) in a Family with Hypocalcemic Tetany. Monatsschr. Kinderheilkd. 1967, 115, 317–320. [Google Scholar]
  132. Hagenbuch, B.; Meier, P.J. Organic Anion Transporting Polypeptides of the OATP/SLC21 Family: Phylogenetic Classification as OATP/SLCO Superfamily, New Nomenclature and Molecular/Functional Properties. Pflügers Arch. Eur. J. Physiol. 2004, 447, 653–665. [Google Scholar] [CrossRef]
  133. Chu, X.-Y.; Bleasby, K.; Yabut, J.; Cai, X.; Chan, G.H.; Hafey, M.J.; Xu, S.; Bergman, A.J.; Braun, M.P.; Dean, D.C.; et al. Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-Glycoprotein. J. Pharmacol. Exp. Ther. 2007, 321, 673–683. [Google Scholar] [CrossRef]
  134. Suzuki, T.; Toyohara, T.; Akiyama, Y.; Takeuchi, Y.; Mishima, E.; Suzuki, C.; Ito, S.; Soga, T.; Abe, T. Transcriptional Regulation of Organic Anion Transporting Polypeptide SLCO4C1 as a New Therapeutic Modality to Prevent Chronic Kidney Disease. J. Pharm. Sci. 2011, 100, 3696–3707. [Google Scholar] [CrossRef] [PubMed]
  135. Li, Q.; Holzwarth, J.A.; Smith, B.; Karaz, S.; Membrez, M.; Sorrentino, V.; Summers, S.; Spears, J.; Migliavacca, E. Impaired Renal Transporter Gene Expression and Uremic Toxin Excretion as Aging Hallmarks in Cats with Naturally Occurring Chronic Kidney Disease. Aging 2024, 16, 13588–13607. [Google Scholar] [CrossRef] [PubMed]
  136. Akiyama, Y.; Kikuchi, K.; Saigusa, D.; Suzuki, T.; Takeuchi, Y.; Mishima, E.; Yamamoto, Y.; Ishida, A.; Sugawara, D.; Jinno, D.; et al. Indoxyl Sulfate Down-Regulates SLCO4C1 Transporter through Up-Regulation of GATA3. PLoS ONE 2013, 8, e66518. [Google Scholar] [CrossRef]
  137. Ailabouni, A.; Prasad, B. Organic Cation Transporters 2: Structure, Regulation, Functions, and Clinical Implications. Drug Metab. Dispos. 2025, 53, 100044. [Google Scholar] [CrossRef]
  138. Motohashi, H.; Nakao, Y.; Masuda, S.; Katsura, T.; Kamba, T.; Ogawa, O.; Inui, K.-I. Precise Comparison of Protein Localization among OCT, OAT, and MATE in Human Kidney. J. Pharm. Sci. 2013, 102, 3302–3308. [Google Scholar] [CrossRef]
  139. Jonker, J.W.; Wagenaar, E.; Van Eijl, S.; Schinkel, A.H. Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations. Mol. Cell. Biol. 2003, 23, 7902–7908. [Google Scholar] [CrossRef]
  140. Giacomini, K.M.; Huang, S.-M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.R.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M.; et al. Membrane Transporters in Drug Development. Nat. Rev. Drug Discov. 2010, 9, 215–236. [Google Scholar] [CrossRef]
  141. Schophuizen, C.M.S.; Wilmer, M.J.; Jansen, J.; Gustavsson, L.; Hilgendorf, C.; Hoenderop, J.G.J.; van den Heuvel, L.P.; Masereeuw, R. Cationic Uremic Toxins Affect Human Renal Proximal Tubule Cell Functioning through Interaction with the Organic Cation Transporter. Pflugers Arch. 2013, 465, 1701–1714. [Google Scholar] [CrossRef]
  142. Severance, A.C.; Sandoval, P.J.; Wright, S.H. Correlation between Apparent Substrate Affinity and OCT2 Transport Turnover. J. Pharmacol. Exp. Ther. 2017, 362, 405–412. [Google Scholar] [CrossRef]
  143. Gessner, A.; König, J.; Fromm, M.F. Clinical Aspects of Transporter-Mediated Drug-Drug Interactions. Clin. Pharmacol. Ther. 2019, 105, 1386–1394. [Google Scholar] [CrossRef]
  144. Galetin, A.; Brouwer, K.L.R.; Tweedie, D.; Yoshida, K.; Sjöstedt, N.; Aleksunes, L.; Chu, X.; Evers, R.; Hafey, M.J.; Lai, Y.; et al. Membrane Transporters in Drug Development and as Determinants of Precision Medicine. Nat. Rev. Drug Discov. 2024, 23, 255–280. [Google Scholar] [CrossRef] [PubMed]
  145. Budiman, T.; Bamberg, E.; Koepsell, H.; Nagel, G. Mechanism of Electrogenic Cation Transport by the Cloned Organic Cation Transporter 2 from Rat. J. Biol. Chem. 2000, 275, 29413–29420. [Google Scholar] [CrossRef] [PubMed]
  146. Gessner, A.; König, J.; Fromm, M.F. Contribution of Multidrug and Toxin Extrusion Protein 1 (MATE1) to Renal Secretion of Trimethylamine-N-Oxide (TMAO). Sci. Rep. 2018, 8, 6659. [Google Scholar] [CrossRef] [PubMed]
  147. Asano, S.; Galetin, A.; Tomita, Y.; Giacomini, K.M.; Chu, X.; Yang, X.; Nakamura, T.; Kusuhara, H.; Sugiyama, Y. Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium). Clin. Pharmacol. Ther. 2025. [Google Scholar] [CrossRef]
  148. Cheung, K.W.K.; Hsueh, C.-H.; Zhao, P.; Meyer, T.W.; Zhang, L.; Huang, S.-M.; Giacomini, K.M. The Effect of Uremic Solutes on the Organic Cation Transporter 2. J. Pharm. Sci. 2017, 106, 2551–2557. [Google Scholar] [CrossRef]
  149. Tanihara, Y.; Masuda, S.; Sato, T.; Katsura, T.; Ogawa, O.; Inui, K.-I. Substrate Specificity of MATE1 and MATE2-K, Human Multidrug and Toxin Extrusions/H+-Organic Cation Antiporters. Biochem. Pharmacol. 2007, 74, 359–371. [Google Scholar] [CrossRef]
  150. Yin, O.Q.; Tomlinson, B.; Chow, M.S. Variability in Renal Clearance of Substrates for Renal Transporters in Chinese Subjects. J. Clin. Pharmacol. 2006, 46, 157–163. [Google Scholar] [CrossRef]
  151. Kajiwara, M.; Terada, T.; Ogasawara, K.; Iwano, J.; Katsura, T.; Fukatsu, A.; Doi, T.; Inui, K. Identification of Multidrug and Toxin Extrusion (MATE1 and MATE2-K) Variants with Complete Loss of Transport Activity. J. Hum. Genet. 2009, 54, 40–46. [Google Scholar] [CrossRef]
  152. Masereeuw, R.; Mutsaers, H.A.M.; Toyohara, T.; Abe, T.; Jhawar, S.; Sweet, D.H.; Lowenstein, J. The Kidney and Uremic Toxin Removal: Glomerulus or Tubule? Semin. Nephrol. 2014, 34, 191–208. [Google Scholar] [CrossRef]
  153. Stevens, L.A.; Coresh, J.; Greene, T.; Levey, A.S. Assessing Kidney Function—Measured and Estimated Glomerular Filtration Rate. N. Engl. J. Med. 2006, 354, 2473–2483. [Google Scholar] [CrossRef]
  154. Khundmiri, S.J.; Chen, L.; Lederer, E.D.; Yang, C.-R.; Knepper, M.A. Transcriptomes of Major Proximal Tubule Cell Culture Models. J. Am. Soc. Nephrol. 2021, 32, 86–97. [Google Scholar] [CrossRef]
Ijms 26 07899 g001
Figure 1. Gene expression of transport proteins mediating L-arginine transport in the renal tubule determined by single-cell RNA data. Proteins are grouped based on their location, facing the urine or blood. Proteins marked with an † or an $ form a heterodimer consisting of an anchor protein and the functional transporter; the underlined protein functions as anchor protein. (a) Data from the Human Protein Atlas (HPA)—the database contains genome-wide single-cell RNA data for 76 cell types. Regarding the tubular system of the kidney, three different cell types are supported: proximal tubule, distal tubule, and collecting duct. Expression data are given in transcripts per million [92,94,95,96,97,98,99,100,101,102]. (b) Kidney Tissue Atlas (KTA) provides data from three cohorts: healthy, chronic kidney disease, and acute kidney injury. The data were clustered not only by cell type markers but also by cell status markers (e.g., enriched cell cycling genes), offering a high single-cell resolution of the tubular system, and containing 14 cell types. For an improved overview, different cell types were combined into seven segments. The highest expression of one cell type per segment is shown. Only data from the healthy cohort without enriched cell status markers were used for this expression analysis. Data are provided as mean logarithmic expression https://www.kpmp.org (accessed on 4 March 2025) [93,103]. (c) Schematic representation of a nephron and its segments and cell type classification by the KTA.
Figure 1. Gene expression of transport proteins mediating L-arginine transport in the renal tubule determined by single-cell RNA data. Proteins are grouped based on their location, facing the urine or blood. Proteins marked with an † or an $ form a heterodimer consisting of an anchor protein and the functional transporter; the underlined protein functions as anchor protein. (a) Data from the Human Protein Atlas (HPA)—the database contains genome-wide single-cell RNA data for 76 cell types. Regarding the tubular system of the kidney, three different cell types are supported: proximal tubule, distal tubule, and collecting duct. Expression data are given in transcripts per million [92,94,95,96,97,98,99,100,101,102]. (b) Kidney Tissue Atlas (KTA) provides data from three cohorts: healthy, chronic kidney disease, and acute kidney injury. The data were clustered not only by cell type markers but also by cell status markers (e.g., enriched cell cycling genes), offering a high single-cell resolution of the tubular system, and containing 14 cell types. For an improved overview, different cell types were combined into seven segments. The highest expression of one cell type per segment is shown. Only data from the healthy cohort without enriched cell status markers were used for this expression analysis. Data are provided as mean logarithmic expression https://www.kpmp.org (accessed on 4 March 2025) [93,103]. (c) Schematic representation of a nephron and its segments and cell type classification by the KTA.
Ijms 26 07899 g001
Ijms 26 07899 g002
Figure 2. Renal handling of L-arginine and L-arginine derivatives in proximal tubule cells. Transport proteins mediating the uptake and/or export of substances are shown in blue, and enzymes involved in metabolism are shown in green. Abbreviations: arginine (Arg), arginine:glycine amidinotransferase (AGAT), Alanine-Glyoxylate Aminotransferase-2 (AGXT2), α-keto-δ asymmetric dimethyl–guanidino valeric acid (ADGV), argininosuccinate lyase (ASL), argininosuccinate synthase (ASS), asymmetric dimethylarginine (ADMA), citrulline (Cit), dimethylaminohydrolase 1 (DDAH1), dimethylamine (DMA), 6-guanidino-2-oxocaproic acid (GOCA), homoarginine (HArg), lysine (Lys), α-keto-∆ symmetric dimethyl–guanidino valeric acid (SDGV), and symmetric dimethylarginine (SDMA).
Figure 2. Renal handling of L-arginine and L-arginine derivatives in proximal tubule cells. Transport proteins mediating the uptake and/or export of substances are shown in blue, and enzymes involved in metabolism are shown in green. Abbreviations: arginine (Arg), arginine:glycine amidinotransferase (AGAT), Alanine-Glyoxylate Aminotransferase-2 (AGXT2), α-keto-δ asymmetric dimethyl–guanidino valeric acid (ADGV), argininosuccinate lyase (ASL), argininosuccinate synthase (ASS), asymmetric dimethylarginine (ADMA), citrulline (Cit), dimethylaminohydrolase 1 (DDAH1), dimethylamine (DMA), 6-guanidino-2-oxocaproic acid (GOCA), homoarginine (HArg), lysine (Lys), α-keto-∆ symmetric dimethyl–guanidino valeric acid (SDGV), and symmetric dimethylarginine (SDMA).
Ijms 26 07899 g002
Table 2. Kinetic parameters for human transport proteins involved in L-arginine and L-arginine derivative transport and associations of diseases with transport function.
Table 2. Kinetic parameters for human transport proteins involved in L-arginine and L-arginine derivative transport and associations of diseases with transport function.
Transport ProteinDirectionCounter ion(s)L-ArginineL-HomoarginineADMASDMA
y+LAT1-4F2hcEffluxNa+, neutral amino acids [32,109,110]Km: 182 ± 35 µM [111]
Vmax: 3.822 ± 0.24 nmol*mg protein−1 *min−1 [111]

Elevated urine and lowered plasma concentrations in LPI patients [69]		No in vitro data

Elevated urine concentrations in LPI patients [69]		No in vitro data

Case report of elevated intracellular ADMA concentrations [112]		No in vitro data

No clinical data
b0,+AT-rBATUptakeNeutral amino acids [82,110]Km: 179.0 µM [113]
Km: 512.6 ± 109.3 µM [27]
Vmax: 1.9 ± 0.1 nmol*mg protein−1 *min−1 [27]

Elevated urine concentrations in cystinuria patients [18] 		Km: 197.0 ± 31 µM [27]
Vmax: 0.7 ± 0.02 nmol*mg protein−1*min−1 [27]

Elevated urine concentrations in cystinuria patients [18] 		Km: not detected
Vmax: >5 ± 0.5 nmol*mg protein−1*min−1 [27]

No clinical data		No in vitro data

No clinical data
OATP4C1Uptake and efflux /Km: 48.1 ± 5.7 µM [29]
Vmax: 500.0 ± 19.9 pmol*mg protein−1*min−1 [29]

No clinical data		Km: 49.9 ± 9.6 µM
Vmax: 355.7 ± 23.0 pmol*mg protein−1*min−1 [29]

No clinical data		Km: 232.1 ± 78.9 µM [29]
Vmax: 351.6 ± 55.0 pmol*mg protein−1*min−1 [29]

No clinical data but increased SLCO4C1 mRNA expression was associated with elevated ADMA elimination in rats [114]		Km: 70 µM [115]

No clinical data
OCT2Uptake/Km: >10,000 µM [28]
Vmax: >50.0 nmol*mg protein−1*min−1 [28]

No clinical data		No in vitro data

No clinical data		Km: 967 ± 143 µM [28]
Vmax: 6.3 ± 0.3 nmol*mg protein−1*min−1 [28]

No clinical data		Km: no saturation [115]

No clinical data
MATE1EffluxH+Substrate [28]

No clinical data		No in vitro data

No clinical data		Transported [28]

No clinical data		Km: 1973 µM [115]

No clinical data
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Scherpinski, L.A.; König, J.; Maas, R. Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives. Int. J. Mol. Sci. 2025, 26, 7899. https://doi.org/10.3390/ijms26167899

AMA Style

Scherpinski LA, König J, Maas R. Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives. International Journal of Molecular Sciences. 2025; 26(16):7899. https://doi.org/10.3390/ijms26167899

Chicago/Turabian Style

Scherpinski, Lorenz A., Jörg König, and Renke Maas. 2025. "Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives" International Journal of Molecular Sciences 26, no. 16: 7899. https://doi.org/10.3390/ijms26167899

APA Style

Scherpinski, L. A., König, J., & Maas, R. (2025). Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives. International Journal of Molecular Sciences, 26(16), 7899. https://doi.org/10.3390/ijms26167899

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop